By VETTAPHARMA reporter: Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd has drawn significant attention from markets and industry watchers with its recent string of deals and strategic moves in the United States, the company’s largest foreign market. But does this activity amount to a full-blown buying spree in the US? Experts say Sun Pharma’s actions suggest focused expansion rather than indiscriminate acquisition.
Past and Ongoing Strategic Deals
Sun Pharma has a history of M&A and investment in the US, especially over the past few years. In 2025, the company made headlines when it acquired Checkpoint Therapeutics, a US-based oncology company, for about $355 million, which added advanced immunotherapies and an FDA-approved cancer drug to its portfolio.
Before that, it completed the merger with Taro Pharmaceutical Industries, a US-listed subsidiary, in 2024 — effectively bringing the business fully under Sun Pharma’s control after it held a majority stake for years.
Sun Pharma has also increased its stake in US-based Pharmazz Inc — a biopharmaceutical firm developing novel therapies — raising its ownership to approximately 22.7% through an investment of up to $25 million.
Recent Rumors: The Organon Push
The most recent spark for debate has been media reports that Sun Pharma is evaluating a potential acquisition of Organon, a US-based pharmaceutical company, for around $10 billion — a deal that would dwarf its recent purchases and be among the biggest overseas acquisitions by an Indian pharma company if it materializes. Such a move would significantly expand Sun Pharma’s footprint in women’s health and biosimilars.
However, the company itself has since clarified those reports as “speculative in nature”, stating that there is no material event requiring disclosure to stock exchanges and dismissing the rumors of a confirmed deal.
This tension — between aggressive acquisition talk and corporate caution — highlights the balance Sun Pharma is trying to strike in its US strategy.
Is It a Spree?
Analysts say the answer depends on how “spree” is defined. If it means multiple strategic acquisitions and targeted investments over several years, then yes — Sun Pharma is actively building its US business. Its acquisitions like Checkpoint Therapeutics and investments in Pharmazz, along with full ownership of Taro, reflect consistent expansion efforts, especially in specialty drugs and biologics.
But if “buying spree” implies rapid, high-volume deals without clear strategy, the evidence is less solid. Sun Pharma’s moves appear methodical, geared toward specific therapeutic areas and long-term growth, rather than a frenzy of broad acquisitions. The company’s denial of the Organon acquisition rumors reinforces this measured posture.
Looking Ahead
Sun Pharma’s US revenue remains critical to its global business, despite challenges such as price pressures and regulatory landscapes prompting strategic shifts in portfolio focus.
Industry watchers will closely monitor whether the Organon pursuit advances into a binding bid or whether Sun continues with similarly targeted investments and acquisitions in the US market. For now, Sun Pharma’s approach seems expansionary but deliberate rather than a full-blown buying spree.
Source credits:
- Business Standard. (2026, January 19). Sun Pharma terms $10 billion Organon acquisition reports ‘speculative’. Click here
- Economic Times. (2026, January). Sun Pharma looks to rise in US with $10 billion Organon buy. Click here
- Economic Times. (2026, January). Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever. Click here
- Financial Express. (2024, August 14). Sun Pharma to invest up to $15 million for 5% stake in US-based Pharmazz. Click here
- Sun Pharmaceutical Industries Ltd. (2024). Merger agreement with Taro Pharmaceutical Industries. Click here
- Chemxpert. (2025). Recent mergers and acquisitions in the pharma sector 2025 roundup. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
